Tevogen Bio Holdings (TVGN) Net Cash Flow (2022 - 2026)

Tevogen Bio Holdings has reported Net Cash Flow for 5 years, with the latest figure at $139933.0 in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 79.78% year-over-year to $139933.0; the trailing twelve-month figure through Mar 2026 stood at -$1.2 million (down 285.41% YoY), and the FY2025 full-year result was -$730623.0, down 416.84% from the prior year.
• Net Cash Flow for Q1 2026 stood at $139933.0, up from -$420283.0 in the prior quarter.
• The five-year high for Net Cash Flow was $1.2 million in Q3 2024, with the low at -$2.2 million in Q2 2023.
• Historically, Net Cash Flow has averaged -$290759.8 across 5 years, with a median of -$45901.0 in 2022.
• The largest YoY upside for Net Cash Flow was 267.97% in 2023 against a maximum downside of 11112.91% in 2023.
• Tevogen Bio Holdings' Net Cash Flow stood at -$13861.0 in 2022, then tumbled by 11112.91% to -$1.6 million in 2023, then soared by 32.59% to -$1.0 million in 2024, then soared by 59.88% to -$420283.0 in 2025, then surged by 133.29% to $139933.0 in 2026.
• The last three Net Cash Flow figures came in at $139933.0 (Q1 2026), -$420283.0 (Q4 2025), and $351865.0 (Q3 2025), per Business Quant data.